期刊
BRITISH JOURNAL OF HAEMATOLOGY
卷 149, 期 6, 页码 890-895出版社
WILEY
DOI: 10.1111/j.1365-2141.2010.08194.x
关键词
hepatitis-associated aplastic anaemia; immunosuppression; bone marrow transplantation
类别
资金
- Agenzia Regionale del Lazio per i Trapianti e le Patologie Connesse
P>In order to assess the epidemiology of Hepatitis-Associated Aplasia (HAA) and compare treatment outcome of HAA with non-HAA patients, we evaluated 3916 aplastic anaemia patients reported to the European Registry between 1990 and 2007. Year, month, season of diagnosis, type and outcome of first-line therapy were analysed. Prevalence of HAA (n = 214) in Europe was 5%. Compared to non-HAA patients, HAA patients were younger (15 vs. 20 years, P < 0 center dot 001), with a male prevalence (68% vs. 58%P = 0 center dot 002), and were treated earlier after diagnosis (46 vs. 62 d; P < 0 center dot 001). No significant differences were found regarding the year or month of diagnosis. No geographic clusters could be identified. Actuarial survival at 10 years after first-line immunosuppression was 69%, and did not differ according to aetiology. The 10-year actuarial survival after transplantation was 70%, and was comparable in HAA and non-HAA patients, when stratified for age and donor type. In a multivariate Cox analysis, increasing age and delayed treatment were significant negative indicators for survival. In conclusion, the incidence of HAA was 5% and was evenly distributed over time and geographic areas in Europe. Treatment outcome and predictive variables, were comparable in patients with or without HAA.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据